Which drug is commonly utilized in vascular surgery patients to inhibit platelet aggregation at the site of intimal trauma?

Which drug is commonly utilized in vascular surgery patients to inhibit platelet aggregation at the site of intimal trauma?

• A. Aspirin
• B. Warfarin
• C. Dextran 40
• D. Clopidogrel

Answer: (C)

In vascular surgery, the drug commonly used to inhibit platelet aggregation at the site of intimal trauma is Dextran 40. This medication acts as a volume expander and has the beneficial effect of reducing blood viscosity. Its mechanism includes the inhibition of platelet aggregation and promotion of microcirculation, which can be particularly advantageous in the postoperative management of vascular patients. While other agents like Aspirin, Warfarin, and Clopidogrel have their roles in anticoagulation and antiplatelet therapy, they serve different purposes. Aspirin and Clopidogrel specifically target platelet aggregation as well, but Dextran 40's unique properties in volume expansion and microcirculation support make it especially relevant in the context of vascular surgery and post-intimal trauma. Warfarin, on the other hand, is primarily an anticoagulant that affects clotting factors rather than directly inhibiting platelet aggregation in the same manner as Dextran 40. Thus, dextran's specific use in this context highlights its effectiveness in enhancing surgical outcomes for vascular patients.

In vascular surgery, the drug commonly used to inhibit platelet aggregation at the site of intimal trauma is Dextran 40. This medication acts as a volume expander and has the beneficial effect of reducing blood viscosity. Its mechanism includes the inhibition of platelet aggregation and promotion of microcirculation, which can be particularly advantageous in the postoperative management of vascular patients.

While other agents like Aspirin, Warfarin, and Clopidogrel have their roles in anticoagulation and antiplatelet therapy, they serve different purposes. Aspirin and Clopidogrel specifically target platelet aggregation as well, but Dextran 40's unique properties in volume expansion and microcirculation support make it especially relevant in the context of vascular surgery and post-intimal trauma. Warfarin, on the other hand, is primarily an anticoagulant that affects clotting factors rather than directly inhibiting platelet aggregation in the same manner as Dextran 40. Thus, dextran's specific use in this context highlights its effectiveness in enhancing surgical outcomes for vascular patients.